塞利西克利布通过抑制铁和改善肠道炎症来缓解性结肠炎
Ya Song1, Qian Song2, Fangyan Tan3
1Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, 74 Linjiang Road, Yuzhong, 400010 Chongqing, China.
Life sciences
|June 12, 2024
概括
塞利西克利布部分抑制铁,一种与性结肠炎 (UC) 相关的细胞死亡形式. 这一发现表明,向铁亡可能为管理UC炎症提供了一种新的治疗策略.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性疾病,其病因不明.
- 铁亡,铁依赖的细胞死亡涉及反应性氧物种 (ROS),与疾病的发展有关.
- 在大肠炎中,一种免疫炎症药物seliciclib的机制在很大程度上是未知的.
研究的目的:
- 为了研究性结肠炎中调节铁的作用.
- 为了探索seliciclib对实验性结肠炎的潜在治疗效果.
- 阐明在UC中的seliciclib作用背后的分子机制.
主要方法:
- 通过使用硫酸 (DSS) 建立了UC的小鼠模型,并用seliciclib治疗.
- 采用了体外模型与脂多糖 (LPS) 诱导和seliciclib治疗.
- 评估了组织病理学,炎症标志物,氧化应激和铁灭调节剂.
主要成果:
- 在DSS诱导的UC小鼠中,施用seliciclib缓解了症状和炎症.
- 该药物在体内和体外模型中部分减轻了铁.
- 生物信息学分析表明,双氧化酶2 (DUOX2) 可能参与UC铁,可能由seliciclib调节.
结论:
- 铁亡与大肠炎的发展有显著的关联.
- 塞利西克利布在调节UC中的铁和炎症方面发挥着至关重要的作用.
- 抑制肠表皮中的铁亡是一种对UC的有希望的治疗途径.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
135
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
135
01:21Drugs for Treatment of Constipation-Predominant IBS
157
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
157
01:17Drugs for Treatment of Diarrhea-Predominant IBS
159
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
159
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
445
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
445
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
162
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
162
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115